Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 3/20 | 0.53 |
| ▸ | BACE1 | P56817 | 10/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4372981 | 1.00 | ATM (0.53) | ATMCTSKBACE1PPARGPPARA | |
| SCHEMBL4750042 | 0.87 | CTSS (0.61) | CTSKBACE1CTSS | |
| SCHEMBL1752665 | 0.81 | CTSS (0.57) | CTSKBACE1CTSS | |
| SCHEMBL29253632 | 0.79 | BACE1 (0.59) | ATMCTSKBACE1CTSSCTSL | |
| SCHEMBL30279569 | 0.79 | BACE1 (0.59) | ATMCTSKBACE1CTSSCTSL | |
| SCHEMBL2393583 | 0.79 | BACE1 (0.59) | ATMCTSKBACE1CTSSCTSL | |
| SCHEMBL8549086 | 0.79 | CTSS (0.64) | ATMCTSKBACE1CTSSCTSL | |
| SCHEMBL8549092 | 0.79 | CTSS (0.64) | ATMCTSKBACE1CTSSCTSL | |
| SCHEMBL3235114 | 0.79 | CTSS (0.51) | ATMCTSKBACE1CTSS | |
| SCHEMBL3495258 | 0.79 | CTSS (0.51) | ATMCTSKBACE1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482343-B2 | Compounds, methods and compositions | CYTOKINETICS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20070135432-A1 | Compounds, methods and compositions | CYTOKINETICS, INC. | 2007-06-14 | — | — | US | disclosed |
| US-7166595-B2 | Compounds, methods and compositions | CYTOKINETICS, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1503993-A4 | COMPOUNDS, METHODS AND COMPOSITIONS | CYTOKINETICS INC (US) | 2006-05-03 | — | — | EP | disclosed |
| EP-1503993-A2 | COMPOUNDS, METHODS AND COMPOSITIONS | Cytokinetics, Inc. (US) | 2005-02-09 | — | — | EP | disclosed |
| US-20040077662-A1 | Compounds, methods and compositions | CYTOKINETICS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2003094839-A2 | PYRIMIDINONE COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077662-A1 | Compounds, methods and compositions | ALPP, PCNA, MKI67 | ATM 1700/4885CTSK 1454/4885BACE1 4501/4885 |
| US-20070135432-A1 | Compounds, methods and compositions | ALPP, PCNA, MKI67 | ATM 1700/4885CTSK 1454/4885BACE1 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.